These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 18945688)

  • 21. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.
    Neuhouser ML; Schenk J; Song YJ; Tangen CM; Goodman PJ; Pollak M; Penson DF; Thompson IM; Kristal AR
    Prostate; 2008 Sep; 68(13):1477-86. PubMed ID: 18618736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age, genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins.
    Meikle AW; Stephenson RA; Lewis CM; Wiebke GA; Middleton RG
    Prostate; 1997 Oct; 33(2):105-11. PubMed ID: 9316651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer.
    Rannikko S; Adlercreutz H
    Prostate; 1983; 4(3):223-9. PubMed ID: 6189106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
    Meunier ME; Neuzillet Y; Raynaud JP; Radulescu C; Ghoneim T; Fiet J; Giton F; Rouanne M; Dreyfus JF; Lebret T; Botto H
    Prostate; 2019 Feb; 79(3):272-280. PubMed ID: 30370569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selenium and Sex Steroid Hormones in a U.S. Nationally Representative Sample of Men: A Role for the Link between Selenium and Estradiol in Prostate Carcinogenesis?
    Van Hemelrijck M; Sollie S; Nelson WG; Yager JD; Kanarek NF; Dobs A; Platz EA; Rohrmann S
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):578-583. PubMed ID: 30482876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders.
    Grzesiak K; Rył A; Baranowska-Bosiacka I; Rotter I; Dołęgowska B; Słojewski M; Sipak-Szmigiel O; Ratajczak W; Lubkowska A; Metryka E; Piasecka M; Laszczyńska M
    Clin Interv Aging; 2018; 13():1375-1382. PubMed ID: 30122909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low 25-OH vitamin D is associated with benign prostatic hyperplasia.
    Haghsheno MA; Mellström D; Behre CJ; Damber JE; Johansson H; Karlsson M; Lorentzon M; Peeker R; Barret-Connor E; Waern E; Sundh V; Ohlsson C; Hammarsten J
    J Urol; 2013 Aug; 190(2):608-14. PubMed ID: 23399651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.
    Schenk JM; Till C; Hsing AW; Stanczyk FZ; Gong Z; Neuhouser ML; Reichardt JK; Hoque AM; Figg WD; Goodman PJ; Tangen CM; Thompson IM
    Cancer Causes Control; 2016 Feb; 27(2):175-82. PubMed ID: 26589415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations.
    Cook MB; Stanczyk FZ; Wood SN; Pfeiffer RM; Hafi M; Veneroso CC; Lynch B; Falk RT; Zhou CK; Niwa S; Emanuel E; Gao YT; Hemstreet GP; Zolfghari L; Carroll PR; Manyak MJ; Sesterhann IA; Levine PH; Hsing AW
    Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1660-1666. PubMed ID: 28830872
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
    J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
    Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia.
    Brochu M; Bélanger A
    Prostate; 1987; 11(1):33-40. PubMed ID: 2443905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of sex steroid hormones in benign prostatic hyperplasia.
    Asiedu B; Anang Y; Nyarko A; Doku DA; Amoah BY; Santa S; Ngala RA; Asare GA
    Aging Male; 2017 Mar; 20(1):17-22. PubMed ID: 28084142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin in relation to prostate cancer and benign prostatic hyperplasia.
    Lagiou P; Signorello LB; Trichopoulos D; Tzonou A; Trichopoulou A; Mantzoros CS
    Int J Cancer; 1998 Mar; 76(1):25-8. PubMed ID: 9533757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.
    Mantzoros CS; Tzonou A; Signorello LB; Stampfer M; Trichopoulos D; Adami HO
    Br J Cancer; 1997; 76(9):1115-8. PubMed ID: 9365156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.
    Nash SH; Till C; Song X; Lucia MS; Parnes HL; Thompson IM; Lippman SM; Platz EA; Schenk J
    Cancer Epidemiol Biomarkers Prev; 2015 Oct; 24(10):1507-15. PubMed ID: 26269564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced circulating androgen bioactivity in patients with prostate cancer.
    Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
    Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry.
    Hsing AW; Stanczyk FZ; Bélanger A; Schroeder P; Chang L; Falk RT; Fears TR
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1004-8. PubMed ID: 17507629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.